Can blood inflammation markers predict the severity of ischemia at myocardial perfusion scintigraphy Les marqueurs d'inflammation sanguine peuvent-ils prédire la sévérité de l'ischémie à la scintigraphie de perfusion myocardique
Medecine Nucleaire, cilt.46, sa.5-6, ss.206-212, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 46 Sayı: 5-6
- Basım Tarihi: 2022
- Doi Numarası: 10.1016/j.mednuc.2022.08.002
- Dergi Adı: Medecine Nucleaire
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE
- Sayfa Sayıları: ss.206-212
- Anahtar Kelimeler: Myocardial perfusion scintigraphy, Coronary artery disease, Complete blood count, Inflammation markers
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: Several studies have reported an association between coronary artery disease (CAD) and complete blood count (CBC) inflammation markers. The role of CBC inflammation markers, which provide an inexpensive and straightforward evaluation in predicting the presence and severity of ischemia in myocardial perfusion scintigraphy (MPS). Materials and methods: Six hundred one patients with suspected coronary artery disease (CAD) who underwent gated single-photon emission computed tomography (SPECT) MPS between June 2016 and June 2020 were evaluated retrospectively. The patients were divided into normal, mild, moderate, and severe ischemia groups according to MPS. Results: In the multivariate regression analysis, the monocyte to high-density lipoprotein cholesterol (HDL-C) ratio (MHR) was found as an independent biomarker that predicted both the presence and severity of ischemia. The cut-off value of the MHR in predicting the presence of ischemia was 1.25, with a sensitivity of 72.3%, a specificity of 83% (AUC ± SE = 0.856 ± 0.015), a positive predictive value of 89.5%, and a negative predictive value of 59.9% (P < 0.001). Conclusion: MHR may be an independent variable in detecting myocardial ischemia in patients with suspected CAD. It may be helpful to detect the patients who have a high risk for CAD.